SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
Q3 2023 Financial Highlights (all metrics compared to Q3 2022 unless otherwise noted)
Recent Operational and Strategic Highlights
Management Commentary
"The results of the quarter highlight the transformation of INVO into a growing, innovative healthcare services company leveraging our INVO Centers to drive IVC volume and obtain a greater share of the total fertility cycle revenue," commented Steve Shum, CEO of INVO. "When you look at the pro forma results for the quarter inclusive of a full quarter contribution from WFI our adjusted EBITDA would have been $(0.3) million, a significant improvement compared to ($2.0) million in the year ago quarter. Equally notable was the fact that our clinics, exclusive of our corporate costs, generated positive net income in the period. With the potential for continued growth from our family of INVO Centers, and more rationalized corporate operating expenses, achieving our stated goal of profitability in 2024 becomes increasingly visible. We look forward to maintaining our focus on driving growth and efficiencies in the business moving forward."
Definitive Merger Agreement
On October 23, 2023, INVO and NAYA, a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, jointly announced that they had entered into a definitive merger agreement (the "Merger") for INVO to acquire NAYA Biosciences in an all-stock transaction. Under the terms of the agreement, NAYA Biosciences' shareholders will receive 7.3333 shares of INVO for each share of NAYA Biosciences at closing, for a total of approximately 18,150,000 shares of INVO. Following the closing of the Merger, the combined company is expected to operate under the name "NAYA Biosciences".
As described in greater detail in the Company's SEC filings and press releases, the Merger remains subject to certain closing conditions including shareholder approval, an estimated $5 million or more (at NAYA's discretion) in interim private financing in INVO at a premium of INVO's market price at time of financing ("Interim PIPE"), and a private offering by the combined company at a target price of $5.00 per common share of INVO. At this time, there are no further updates on the satisfaction of the closing conditions.
"We are excited by the opportunity to merge INVO and NAYA and having the financial resources to advance both the fertility and newly acquired oncology operations," commented Shum. "We believe this combination provides the benefit of bringing our existing, revenue-generating operations from our fertility business with an ability to further grow these activities, along with the significant upside potential of innovative cancer therapeutics."
Financial Results
Only partial quarter results from WFI, which INVO acquired on August 10, 2023, are included in the results for the three months ended September 30, 2023. Where applicable, pro forma results are provided as if the acquisition closed on July 1, 2023 and therefore would have been included for the entire quarter.
Revenue for the three months ended September 30, 2023, was $974,894 compared to $235,321 for the three months ended September 30, 2023, an increase of 314%. Pro forma revenue for Q3 2023, assuming a full quarter of WFI, would have been $1,492,520, an increase of 534%.
Clinic revenue from the Company's consolidated INVO Centers was $947,891 during the third quarter of 2023, an increase of 437% compared to $176,395 for the three months ended September 30, 2022. Revenue from all INVO Centers combined was $1,352,881, an increase of 201% compared to the year-ago period.
Selling, general and administrative expenses for the three months ended September 30, 2023, were approximately $1.3 million compared to approximately $2.3 million for the three months ended September 30, 2022. The decrease of approximately $1.0 million, or approximately 46%, was primarily the result of approximately $1.1 million in decreased personnel expenses and approximately $0.2 million in decreased marketing expenses, and was partially offset by a $0.1 million increase in professional fees and a $0.1 million increase in operational expenses related to WFI.
R&D expenses were approximately $0.0 million and $0.2 million for the three months ended September 30, 2023, and September 30, 2022, respectively. The decrease is a result of the Company receiving FDA clearance in June 2023 for its 510(k) application.
Total operating costs were $1.9 million and $2. 8 million for the three months ended September 30, 2023, and September 30, 2022, respectively.
Net loss was $(1.2) million and $(2.5) million for the three months ended September 30, 2023, and September 30, 2022, respectively. Pro forma net loss, assuming a full quarter contribution from WFI, would have been approximately $(1.0) million.
Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended September 30, 2023, was $(0.6) million, compared to adjusted EBITDA of $(2.0) million for the quarter ended September 30, 2022. Pro forma adjusted EBITDA, assuming a full quarter contribution from WFI, would have been approximately $(0.3) million.
As of September 30, 2023, the Company had approximately $1.1 million in cash.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
Conference Call Details
INVO will announce details for a conference call in a future press release. The conference call is expected to be held after November 20, 2023, and following the progress of certain closing conditions pertaining to the Merger.
About INVO Bioscience
We are a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT
INVO Bioscience:
Steve Shum
978-878-9505
This email address is being protected from spambots. You need JavaScript enabled to view it.
INVO Investor Contact:
Robert Blum (Lytham Partners, LLC)
602-889-9700
This email address is being protected from spambots. You need JavaScript enabled to view it.
INVO BIOSCIENCE, INC. | |||||
CONSOLIDATED BALANCE SHEETS | |||||
June 30, 2023 | December 31, 2022 | ||||
ASSETS | |||||
Current assets | |||||
Cash | $ | 1,055,544 | $ | 90,135 | |
Accounts receivable | 116,781 | 77,149 | |||
Inventory | 254,220 | 263,602 | |||
Prepaid expenses and other current assets | 365,227 | 190,201 | |||
Total current assets | 1,791,772 | 621,087 | |||
Property and equipment, net | 772,447 | 436,729 | |||
Lease right of use | 5,858,042 | 1,808,034 | |||
Intangible assets | 1,750,000 | - | |||
Goodwill | 8,224,708 | - | |||
Investment in joint ventures | 1,079,202 | 1,237,865 | |||
Total assets | $ | 19,476,171 | $ | 4,103,715 | |
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | |||||
Current liabilities | |||||
Accounts payable and accrued liabilities | $ | 1,851,783 | $ | 1,349,038 | |
Accrued compensation | 590,598 | 946,262 | |||
Notes payable, current portion | 822,574 | 100,000 | |||
Notes payable, related party | 880,000 | 662,644 | |||
Deferred revenue | 229,921 | 119,876 | |||
Lease liability, current portion | 385,836 | 231,604 | |||
Other current liabilities | 123,432 | - | |||
Total current liabilities | 4,884,144 | 3,409,424 | |||
Notes payable, net of current portion | 1,095,000 | - | |||
Lease liability, net of current portion | 5,622,279 | 1,669,954 | |||
Deferred tax liability | 1,949 | 1,949 | |||
Additional payments for acquisition | 7,500,000 | - | |||
Total liabilities | 19,103,372 | 5,081,327 | |||
Stockholders' equity (deficit) | |||||
Common Stock, $.0001 par value; 50,000,000 shares authorized; 2,474,756 and 608,611 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 247 | 61 | |||
Additional paid-in capital | 56,195,915 | 48,805,860 | |||
Accumulated deficit | (55,823,363) | (49,783,533) | |||
Total stockholders' equity (deficit) | 372,799 | (977,612) | |||
- | |||||
Total liabilities and stockholders' equity (deficit) | $ | 19,476,171 | $ | 4,103,715 |
INVO BIOSCIENCE, INC. | ||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
Revenue: | ||||||||||||
Clinic revenue | $ | 947,891 | $ | 176,395 | $ | 1,499,636 | $ | 394,601 | ||||
Product revenue | 27,003 | 58,926 | 139,185 | 149,453 | ||||||||
Total revenue | 974,894 | 235,321 | 1,638,821 | 544,054 | ||||||||
Operating expenses: | ||||||||||||
Cost of revenue | 580,968 | 248,977 | 1,047,687 | 616,184 | ||||||||
Selling, general and administrative | 1,257,044 | 2,316,763 | 5,630,487 | 7,308,478 | ||||||||
Research and development | 2,668 | 175,267 | 160,038 | 470,208 | ||||||||
Depreciation and amortization | 20,504 | 19,732 | 59,296 | 57,361 | ||||||||
Total operating expenses | 1,861,184 | 2,760,739 | 6,897,508 | 8,452,231 | ||||||||
Loss from operations | (886,290) | (2,525,418) | (5,258,687) | (7,908,177) | ||||||||
Other income (expense): | ||||||||||||
Gain (loss) from equity method joint ventures | (8,163) | (21,470) | (32,110) | (210,565) | ||||||||
Interest income | - | 34 | - | 307 | ||||||||
Interest expense | (352,085) | (1,761) | (743,866) | (3,319) | ||||||||
Foreign currency exchange loss | (16) | (1,008) | (416) | (2,922) | ||||||||
Total other income (expense) | (360,264) | (24,205) | (776,392) | (216,499) | ||||||||
Loss before income taxes | (1,246,554) | (2,549,623) | (6,035,079) | (8,124,676) | ||||||||
Income taxes | 1,886 | - | 4,751 | 800 | ||||||||
Net loss | $ | (1,248,440) | (2,549,623) | (6,039,830) | (8,125,476) | |||||||
Net loss per common share: | ||||||||||||
Basic | $ | (0.70) | $ | (4.19) | $ | (5.76) | $ | (13.42) | ||||
Diluted | $ | (0.70) | $ | (4.19) | $ | (5.76) | $ | (13.42) | ||||
Weighted average number of common shares outstanding: | ||||||||||||
Basic | 1,776,898 | 607,783 | 1,048,115 | 605,356 | ||||||||
Diluted | 1,776,898 | 607,783 | 1,048,115 | 605,356 | ||||||||
ADJUSTED EBITDA | ||||||||||
Three Months Ended | Nine Months Ended | |||||||||
September 30 | September 30 | |||||||||
2023 | 2022 | 2023 | 2022 | |||||||
Net loss | $ (1,248,440) | $ (2,549,623) | $ (6,039,830) | $ (8,125,476) | ||||||
Interest expense | 40,924 | 1,727 | 131,607 | 3,012 | ||||||
Foreign currency exchange loss | 16 | 1,008 | 416 | 2,922 | ||||||
Stock-based compensation | 13,918 | 79,479 | 309,659 | 524,793 | ||||||
Stock option expense | 251,555 | 426,143 | 904,305 | 1,287,427 | ||||||
Non-cash compensation for services | 45,000 | 45,000 | 135,000 | 75,000 | ||||||
Amortization of debt discount | 311,161 | - | 612,259 | - | ||||||
Depreciation and amortization | 20,504 | 19,732 | 59,296 | 57,361 | ||||||
Adjusted EBITDA | $ (565,362) | $ (1,976,534) | $ (3,887,288) | $ (6,174,961) | ||||||
Proforma net loss | $ (998,380) | $ (2,057,245) | $ (5,128,430) | $ (9,571,686) | ||||||
Interest expense | 40,924 | 1,727 | 131,607 | 3,012 | ||||||
Foreign currency exchange loss | 16 | 1,008 | 416 | 2,922 | ||||||
Stock-based compensation | 13,918 | 79,479 | 309,659 | 524,793 | ||||||
Stock option expense | 251,555 | 426,143 | 904,305 | 1,287,427 | ||||||
Non-cash compensation for services | 45,000 | 45,000 | 135,000 | 75,000 | ||||||
Amortization of debt discount | 311,161 | - | 612,259 | - | ||||||
Depreciation and amortization | 20,504 | 19,732 | 59,296 | 57,361 | ||||||
Proforma adjusted EBITDA | $ (315,302) | $ (1,484,156) | $ (2,975,888) | $ (7,621,171) | ||||||
INVO Center RESULTS | |||||||||||
The following tables summarize the combined financial information of our consolidated and equity method joint venture INVO Centers: | |||||||||||
For the Three Months Ended | For the Nine Months Ended | ||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||
Statements of operations: | |||||||||||
Operating revenue | $ 1,352,881 | $ 502,993 | $ 2,712,021 | $ 1,170,378 | |||||||
Operating expenses | (1,231,274) | (721,663) | (2,745,932) | (2,123,480) | |||||||
Net income | $ 121,607 | $ (218,670) | $ (33,911) | $ (953,102) | |||||||
September 30, | December 31, | ||||||||||
Balance sheets: | |||||||||||
Current assets | $ 577,496 | $ 447,422 | |||||||||
Long-term assets | 3,780,410 | 2,000,841 | |||||||||
Current liabilities | (1,158,194) | (735,767) | |||||||||
Long-term liabilities | (2,777,250) | (1,042,167) | |||||||||
Net assets | $ 422,462 | $ 670,329 | |||||||||
| Last Trade: | US$1.02 |
| Daily Volume: | 5,145,882 |
August 14, 2024 January 23, 2024 December 11, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
